CHRS News & Events

Coherus Oncology and Zumutor Biologics announced a clinical collaboration and supply agreement to conduct a Phase 1 trial of ZM008, a NK checkpoint anti-LLT1 monoclonal antibody in combination with Loqtorzi, a PD-1 inhibitor. The study will enroll patients with colorectal, head and neck, non-small cell lung cancer, clear cell renal cell carcinoma and urothelial cancers, among other solid tumors. Under the terms of the greement, Coherus will provide Loqtorzi to Zumutor, which will be the sponsor of the Phase 1 clinical combination trial. Zumutor and Coherus each retain all commercial rights to their respective compounds, as monotherapies or combination therapies.

Reports Q1 revenue $12.31M, consensus $14.34M. "We are executing well on our integrated financial, commercial and development strategy that maximizes LOQTORZI's potential in NPC and in combination with our pipeline products." said Denny Lanfear, Coherus Chairman and Chief Executive Officer. "We also continue to explore opportunities across cancers and non-proprietary novel combinations with tagmokitug, our potentially best-in-class CCR8 Treg depleter, and are encouraged given our previously reported clinical data including anti-tumor activity, safety data, tumor biomarker data and PK data."